These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 79764)

  • 21. A clinical trial of i.v. tetravalent hyperimmune Pseudomonas globulin G in burned patients.
    Hunt JL; Purdue GF
    J Trauma; 1988 Feb; 28(2):146-51. PubMed ID: 3126302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the effectiveness of antipseudomonas biological management in the control of infection in burn patients.
    Gonzáles Ayala SE; Daroda M; Villa J; Cecchini E; Vich J
    Panminerva Med; 1983; 25(3):203-8. PubMed ID: 6422426
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunoprophylaxis of Pseudomonas aeruginosa.
    Young LS; Armstrong D; Markley K
    Ann Intern Med; 1971 Jun; 74(6):1012-3. PubMed ID: 4996343
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevention of invasive pseudomonas infection in burns with a new vaccine.
    Alexander JW; Fisher MW; MacMillan BG; Altemeier WA
    Arch Surg; 1969 Aug; 99(2):249-56. PubMed ID: 4978523
    [No Abstract]   [Full Text] [Related]  

  • 25. Early protection by vaccines against Pseudomonas aeruginosa colonizing burns.
    Jones RJ; Lowbury EJ
    Br J Exp Pathol; 1972 Dec; 53(6):659-64. PubMed ID: 4630411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active and passive immunization with Pseudomonas aeruginosa ribosomal vaccines and antisera in the burned rat model.
    Lieberman MM; Walker HL; Ayala E; Chapa I
    J Surg Res; 1986 Feb; 40(2):138-44. PubMed ID: 3080639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical use of a Soviet polyvalent corpuscular pyocyanic vaccine for the prevention of Pseudomonas aeruginosa infection in thermal burn victims].
    Gerasimova LI; Moroz AF; Radkevich SA; Sveshnikov AI; Mizikin EV
    Khirurgiia (Mosk); 1980 Nov; (11):36-41. PubMed ID: 6777578
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunological control of Pseudomonas infection in burn patients: a clinical evaluation.
    Alexander JW; Fisher MW; MacMillan BG
    Arch Surg; 1971 Jan; 102(1):31-5. PubMed ID: 4992359
    [No Abstract]   [Full Text] [Related]  

  • 29. Pseudomonas aeruginosa infection: pathogenesis and therapy.
    Pennington JE
    Compr Ther; 1979 May; 5(5):14-22. PubMed ID: 110508
    [No Abstract]   [Full Text] [Related]  

  • 30. Pseudomonas aeruginosa: prevention better than cure?
    Mellor JA; Miler JJ
    Dev Biol Stand; 1979; 43():53-9. PubMed ID: 118071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection].
    Minukhin VV; Tsyganenko AIa
    Antibiot Khimioter; 1989 Apr; 34(4):282-6. PubMed ID: 2502083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A reduction of Pseudomonas septicemias in burned patients by the immune process.
    Pierson C; Feller I
    Surg Clin North Am; 1970 Dec; 50(6):1377-83. PubMed ID: 4922825
    [No Abstract]   [Full Text] [Related]  

  • 33. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection.
    Montie TC; Drake D; Sellin H; Slater O; Edmonds S
    Antibiot Chemother (1971); 1987; 39():233-48. PubMed ID: 3118785
    [No Abstract]   [Full Text] [Related]  

  • 34. An evaluation of five percent sulfamylon cream in control of experimental burn wound sepsis.
    Skornik WA; Dressler DP
    Surgery; 1973 Oct; 74(4):540-4. PubMed ID: 4199616
    [No Abstract]   [Full Text] [Related]  

  • 35. Pivotal advance: glycyrrhizin restores the impaired production of beta-defensins in tissues surrounding the burn area and improves the resistance of burn mice to Pseudomonas aeruginosa wound infection.
    Yoshida T; Yoshida S; Kobayashi M; Herndon DN; Suzuki F
    J Leukoc Biol; 2010 Jan; 87(1):35-41. PubMed ID: 19843573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Polish preparations for preventing and treating infections caused by Pseudomonas aeruginosa].
    Schiller B; Buchowicz I; Lysakowska E; Sakiel S; Korbecki M
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Apr; (4):30-2. PubMed ID: 2409720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection and cross-infection in a new Burns Centre.
    Barclay TL; Dexter F
    Br J Surg; 1968 Mar; 55(3):197-202. PubMed ID: 4966047
    [No Abstract]   [Full Text] [Related]  

  • 38. Cefsulodin therapy for infections due to Pseudomonas aeruginosa in patients with burns.
    Heimbach DM
    Rev Infect Dis; 1984; 6 Suppl 3():S744-50. PubMed ID: 6443775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of new potent topical antibacterial agent for the control of infection in the burn wound.
    Georgiade N; Georgiade R; Garrett W
    Plast Reconstr Surg; 1967 Apr; 39(4):349-56. PubMed ID: 4960627
    [No Abstract]   [Full Text] [Related]  

  • 40. An outbreak of multidrug-resistant Pseudomonas aeruginosa in a burns service in the North of England: challenges of infection prevention and control in a complex setting.
    Decraene V; Ghebrehewet S; Dardamissis E; Huyton R; Mortimer K; Wilkinson D; Shokrollahi K; Singleton S; Patel B; Turton J; Hoffman P; Puleston R
    J Hosp Infect; 2018 Dec; 100(4):e239-e245. PubMed ID: 30012376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.